The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study

Blood

Volumn 106, Issue 9, 2005, Pages 3049-3054

  Prandoni, Paolo ^a   Siragusa, Sergio ^b   Girolami, Bruno ^b   Fabris, Fabrizio ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 27644563148     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-0912     Document Type: Article

References (17)

1. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest. 2004;126:331S-337S.
2. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30:273-283.
3. Chong BH, Chong JH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther. 2004;2:547-559.
4. Picker SM, Gathof BS. Pathophysiology, epidemiology, diagnosis and treatment of heparin-induced thrombocytopenia. Eur J Med Res. 2004;9:180-185.
5. Warkentin TE, Levine MN, Hirsh J, et al. Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
6. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol. 2002;118:1137-42.
7. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2001;10:35-45.
8. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med. 2002;252:149-154.
9. Eichler P, Budde U, Haas S, et al. First workshop for the detection of heparin-induced antibodies: validation of the Heparin-Induced Platelet Activation Test (HIPA) in comparison with PF4/Heparin ELISA. Thromb Haemost. 1999;81:625-629.
10. Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G. Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost. 2003;1:2696-2697.
11. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-2959.
12. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-407.
13. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136:210-215.
14. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.
15. Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore PJ, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
16. Locke CFS, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar. Thrombosis J. 2005;3:4.
17. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med. 2002;126:1415-1423.